Trial Profile

Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma R/M SCCHN

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benmelstobart (Primary) ; Carboplatin; Cisplatin; Fluorouracil
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com